Paul Goldenheim

Paul Goldenheim was Purdue Pharma’s former chief scientist and medical director, and one of three senior executives who pleaded guilty in the federal case over the marketing of OxyContin. The book traces his public role not through a personal biography but through the 2007 settlement and sentencing: a corporate admission of fraudulent marketing, a defense that separated the executives from personal wrongdoing, and a courtroom encounter with families who had lost children. In southwest Virginia, where the region had seen as many as two hundred OxyContin-related deaths, the question was not only what the company would pay, but whether its leaders would acknowledge the harm.

Corporate Role and the Case

Goldenheim had served as Purdue Pharma’s chief scientist and medical director. He left the company in 2004, but remained one of the three executives named in the federal resolution, alongside Howard Udell and Michael Friedman. The case concerned a marketing campaign that presented OxyContin as less prone to abuse and less likely to cause narcotic side effects than immediate-release versions of the drug.

In May 2007, John Brownlee announced the settlement in a downtown Roanoke office building. Purdue Pharma agreed to plead guilty to felony misbranding and admitted that, over six years, it had fraudulently marketed OxyContin’s abuse risk and side effects. The company’s conduct included claims about the drug’s timed-release mechanism; Purdue had dropped insert language about that mechanism’s ability to reduce a drug’s abuse liability in 2001. The book also notes that falsified charts had been created by Purdue, but does not identify Goldenheim as their author or establish his personal role in making them.

The company agreed to pay $600 million in fines and resolve federal criminal and civil misbranding charges. Its three senior executives, including Goldenheim, pleaded guilty to misdemeanor versions of the offense. Their $34.5 million in fines was paid by the firm on their behalf. The broader figure reported for the fine was $634.5 million, with $7.5 million assessed against Goldenheim and an additional $5,000 fine for each executive. The corporate and executive penalties represented about 90 percent of Purdue Pharma’s profits from OxyContin’s 1996 launch through 2001, and constituted the eleventh-largest fine paid by a pharmaceutical company in the Justice Department’s history.

Arrival and Courtroom Reckoning

The executives were due to appear for sentencing in Abingdon in July. They had flown in from Connecticut the night before and stayed at the historic Martha Washington Inn beside the courthouse. Their lawyers asked the judge to let them enter through a back door, away from protesters. James P. Jones refused: the executives would enter by the front, as other people did.

Outside the hearing, parents read aloud the names of people who had died. Ed Bisch had printed the names from memorials on his message board; the list had grown to more than fifty pages. Their voices sometimes faltered as they read. That public roll call turned the proceeding from a dispute over corporate penalties into a direct confrontation between executives and families bearing the losses associated with OxyContin.

Barry Meier, a journalist who had followed the case, recalled that he and a photographer stood as the executives appeared to notice them. Goldenheim looked steadily toward the camera, while Udell and Friedman glanced away. The account describes their reactions but does not assign Goldenheim a motive or explain what he was thinking. His composure in that moment stands beside the scene’s wider pressure: the settlement had been announced, but grieving parents were still asking the court to make the executives face them.

Defense and Personal Accountability

At sentencing, lawyers for the executives repeatedly argued that the shame of criminal charges was itself punishment and that the men had personally done nothing wrong. Goldenheim’s lawyer described him as being in agony over the charge, and argued that calling him a criminal was an extraordinarily harsh judgment of someone who had done much good and, under the agreed statement of facts, had done nothing wrong. The defense thus placed a boundary between the company’s admitted misbranding and the individual culpability of the executives who had led its divisions.

The book distinguishes Goldenheim’s defense from arguments made on behalf of the other executives. Udell’s lawyer cited his role in withdrawing the 160-milligram pill and supporting prescription monitoring; Friedman’s lawyer listed Purdue’s antidiversion brochures, antifraud prescription pads, law-enforcement liaison unit, and changes to sales compensation. Those claims were not presented as Goldenheim’s individual actions. The broader defense, however, returned to the assertion that OxyContin’s benefits outweighed its risks, even in the face of testimony from grieving families. The contrast is central to Goldenheim’s appearance in the case: a corporate admission and a collective misdemeanor plea coexisted with lawyers’ insistence that the individuals had not personally committed wrongdoing.

Lee Nuss, whose son Randy had died, had urged the judge to reject the plea agreement, arguing that money alone meant little and that punishment should fit the crime. She carried a small brass urn containing Randy’s ashes, which Purdue’s lawyers had previously had removed from Karen White’s whistle-blower trial. In court, she identified the ashes as belonging to her son and connected his death to OxyContin, addressing Goldenheim along with Udell and Friedman. She waved the urn rather than throwing it. Her action made the loss physically present in a proceeding otherwise conducted through legal charges, agreed facts, and financial penalties.

Narrative Significance

Goldenheim’s part in the book is defined by the distance between corporate responsibility and personal accountability. The settlement established that Purdue Pharma had fraudulently marketed OxyContin’s risks; the executives accepted misdemeanor pleas, while their lawyers disputed the implication that this made them personally culpable. Against those arguments, the parents brought names, testimony, and, in Nuss’s case, an urn into the courtroom. The scene does not resolve the tension by claiming access to Goldenheim’s private thoughts. Instead, it shows him at the point where the company’s legal settlement met the human consequences its victims’ families demanded the court recognize.